Copy For Citation
Akdede B., Alptekin K., Kitis A., Arkar H., Akvardar Y.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol.29, no.2, pp.233-238, 2005 (SCI-Expanded)
Article / Review
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
Science Citation Index Expanded (SCI-EXPANDED), Scopus
cognitive function, quetiapine, schizophrenia, SYNDROME SCALE PANSS, NEUROPSYCHOLOGICAL DEFICITS, HALOPERIDOL, RISPERIDONE, CLOZAPINE, OLANZAPINE, ANTIPSYCHOTICS, IMPROVEMENT, FUMARATE, SEROQUEL
Marmara University Affiliated:
Objective: All atypical antipsychotic drugs with complex pharmacology have been shown to improve some, but not all, domains of cognitive function, including quetiapine, i.e., the agent with the most rapid dissociation from dopamine receptors and a relatively weak serotonin antagonism. The present study was to evaluate which, if any, areas of cognition improve in patients with schizophrenia, following a brief treatment with quetiapine.